The small GTPase Rab5c is a key regulator of trafficking of the CD93/Multimerin-2/β1 integrin complex in endothelial cell adhesion and migration.
C1qRp
Cell polarity
Cell spreading
Moesin
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
28 05 2019
28 05 2019
Historique:
received:
26
03
2019
accepted:
20
05
2019
entrez:
30
5
2019
pubmed:
30
5
2019
medline:
11
4
2020
Statut:
epublish
Résumé
In the endothelium, the single-pass membrane protein CD93, through its interaction with the extracellular matrix protein Multimerin-2, activates signaling pathways that are critical for vascular development and angiogenesis. Trafficking of adhesion molecules through endosomal compartments modulates their signaling output. However, the mechanistic basis coordinating CD93 recycling and its implications for endothelial cell (EC) function remain elusive. Human umbilical vein ECs (HUVECs) and human dermal blood ECs (HDBEC) were used in this study. Fluorescence confocal microscopy was employed to follow CD93 retrieval, recycling, and protein colocalization in spreading cells. To better define CD93 trafficking, drug treatments and transfected chimeric wild type and mutant CD93 proteins were used. The scratch assay was used to evaluate cell migration. Gene silencing strategies, flow citometry, and quantification of migratory capability were used to determine the role of Rab5c during CD93 recycling to the cell surface. Here, we identify the recycling pathway of CD93 following EC adhesion and migration. We show that the cytoplasmic domain of CD93, by its interaction with Moesin and F-actin, is instrumental for CD93 retrieval in adhering and migrating cells and that aberrant endosomal trafficking of CD93 prevents its localization at the leading edge of migration. Moreover, the small GTPase Rab5c turns out to be a key component of the molecular machinery that is able to drive CD93 recycling to the EC surface. Finally, in the Rab5c endosomal compartment CD93 forms a complex with Multimerin-2 and active β1 integrin, which is recycled back to the basolaterally-polarized cell surface by clathrin-independent endocytosis. Our findings, focusing on the pro-angiogenic receptor CD93, unveil the mechanisms of its polarized trafficking during EC adhesion and migration, opening novel therapeutic opportunities for angiogenic diseases.
Sections du résumé
BACKGROUND
In the endothelium, the single-pass membrane protein CD93, through its interaction with the extracellular matrix protein Multimerin-2, activates signaling pathways that are critical for vascular development and angiogenesis. Trafficking of adhesion molecules through endosomal compartments modulates their signaling output. However, the mechanistic basis coordinating CD93 recycling and its implications for endothelial cell (EC) function remain elusive.
METHODS
Human umbilical vein ECs (HUVECs) and human dermal blood ECs (HDBEC) were used in this study. Fluorescence confocal microscopy was employed to follow CD93 retrieval, recycling, and protein colocalization in spreading cells. To better define CD93 trafficking, drug treatments and transfected chimeric wild type and mutant CD93 proteins were used. The scratch assay was used to evaluate cell migration. Gene silencing strategies, flow citometry, and quantification of migratory capability were used to determine the role of Rab5c during CD93 recycling to the cell surface.
RESULTS
Here, we identify the recycling pathway of CD93 following EC adhesion and migration. We show that the cytoplasmic domain of CD93, by its interaction with Moesin and F-actin, is instrumental for CD93 retrieval in adhering and migrating cells and that aberrant endosomal trafficking of CD93 prevents its localization at the leading edge of migration. Moreover, the small GTPase Rab5c turns out to be a key component of the molecular machinery that is able to drive CD93 recycling to the EC surface. Finally, in the Rab5c endosomal compartment CD93 forms a complex with Multimerin-2 and active β1 integrin, which is recycled back to the basolaterally-polarized cell surface by clathrin-independent endocytosis.
CONCLUSIONS
Our findings, focusing on the pro-angiogenic receptor CD93, unveil the mechanisms of its polarized trafficking during EC adhesion and migration, opening novel therapeutic opportunities for angiogenic diseases.
Identifiants
pubmed: 31138217
doi: 10.1186/s12964-019-0375-x
pii: 10.1186/s12964-019-0375-x
pmc: PMC6537425
doi:
Substances chimiques
Blood Proteins
0
Integrin beta1
0
Membrane Glycoproteins
0
Receptors, Complement
0
complement 1q receptor
0
multimerin
0
RAB5C protein, human
EC 3.6.1.-
rab5 GTP-Binding Proteins
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
55Références
Cold Spring Harb Perspect Biol. 2014 Oct 23;6(11):a022616
pubmed: 25341920
Oncotarget. 2014 May 15;5(9):2750-60
pubmed: 24809468
Sci Rep. 2016 Mar 09;6:22749
pubmed: 26956714
Nat Cell Biol. 2012 Dec;14(12):1235-43
pubmed: 23196841
J Cell Sci. 2015 Mar 1;128(5):839-52
pubmed: 25663697
Matrix Biol. 2018 Oct;71-72:1-9
pubmed: 29625183
Angiogenesis. 2012 Jun;15(2):187-97
pubmed: 22327338
J Cell Physiol. 2017 Jul;232(7):1767-1773
pubmed: 27859225
Nat Rev Mol Cell Biol. 2009 Sep;10(9):609-22
pubmed: 19696798
Nat Rev Mol Cell Biol. 2018 Nov;19(11):679-696
pubmed: 30194414
Nat Commun. 2016 Nov 23;7:13546
pubmed: 27876801
J Cell Sci. 2014 Aug 1;127(Pt 15):3199-204
pubmed: 24951115
Small GTPases. 2014;5:e29469
pubmed: 24914539
Nat Med. 2012 Oct;18(10):1560-9
pubmed: 22983395
Biochem Biophys Res Commun. 2017 Jan 29;483(1):482-487
pubmed: 28007601
Cell. 1991 Mar 8;64(5):915-25
pubmed: 1900457
Curr Biol. 2015 Aug 31;25(17):2325-31
pubmed: 26299518
Microcirculation. 2017 Apr;24(3):
pubmed: 28129474
Dev Cell. 2010 Jan 19;18(1):39-51
pubmed: 20152176
Nature. 2012 May 23;485(7399):465-70
pubmed: 22622570
Cancer Res. 2015 Nov 1;75(21):4504-16
pubmed: 26363010
Eur J Cell Biol. 2008 Sep;87(8-9):641-7
pubmed: 18375013
Curr Opin Cell Biol. 2011 Aug;23(4):377-82
pubmed: 21592758
Nat Rev Cancer. 2012 Oct;12(10):699-709
pubmed: 23001349
Nat Rev Mol Cell Biol. 2009 Dec;10(12):843-53
pubmed: 19904298
J Immunol. 2016 Jul 15;197(2):480-90
pubmed: 27288534
Nature. 2004 May 20;429(6989):309-14
pubmed: 15152255
Biochemistry. 2007 Apr 3;46(13):3998-4005
pubmed: 17348685
Physiology (Bethesda). 2011 Oct;26(5):326-33
pubmed: 22013191
Am J Transl Res. 2015 Oct 15;7(10):1675-98
pubmed: 26692917
Curr Opin Cell Biol. 2011 Oct;23(5):607-14
pubmed: 21924601
Matrix Biol. 2017 Dec;64:112-127
pubmed: 28912033
Oncogene. 2017 Nov 2;36(44):6097-6108
pubmed: 28671670
PLoS One. 2014 Feb 28;9(2):e90384
pubmed: 24587345
Nat Rev Mol Cell Biol. 2011 Aug 23;12(9):551-64
pubmed: 21860391
J Cell Biol. 1998 Feb 23;140(4):885-95
pubmed: 9472040
Eur Biophys J. 2011 Sep;40(9):1013-27
pubmed: 21833780
FEBS Lett. 1995 Jun 5;366(1):65-71
pubmed: 7789520
Curr Biol. 2011 Feb 8;21(3):R126-36
pubmed: 21300279
FEBS Lett. 2008 Jul 23;582(17):2542-8
pubmed: 18582465
Oncotarget. 2016 Mar 1;7(9):10090-103
pubmed: 26848865
Int J Biochem Cell Biol. 1998 Feb;30(2):179-84
pubmed: 9608671
PLoS Genet. 2017 Jul 13;13(7):e1006780
pubmed: 28704371
Curr Opin Cell Biol. 2010 Aug;22(4):519-27
pubmed: 20439156
J Cell Biol. 2012 Jun 25;197(7):983-96
pubmed: 22734003
Immunology. 2005 May;115(1):63-73
pubmed: 15819698
Cell Res. 2012 Oct;22(10):1479-501
pubmed: 22825554
Trends Cell Biol. 2014 Jul;24(7):407-15
pubmed: 24675420
Methods. 2017 Feb 15;115:42-54
pubmed: 28131869
Histochem Cell Biol. 2012 Sep;138(3):419-33
pubmed: 22644377
Sci Rep. 2016 Oct 11;6:34987
pubmed: 27725698
J Clin Invest. 2018 Aug 1;128(8):3280-3297
pubmed: 29763414
Nat Rev Mol Cell Biol. 2001 Feb;2(2):107-17
pubmed: 11252952
Biophys J. 2018 Jun 19;114(12):2887-2899
pubmed: 29925025
Semin Cell Dev Biol. 2018 Sep;81:2-12
pubmed: 28739340
Nature. 2000 Sep 14;407(6801):249-57
pubmed: 11001068
PLoS One. 2012;7(12):e51647
pubmed: 23272129